Linked Life Data

9270246

Source:http://linkedlifedata.com/resource/pubmed/id/9270246

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1997-9-11
pubmed:abstractText
The aim of this study was to assess the feasibility and effectiveness of intrapleural administration of recombinant human interleukin-2 (rhIL-2) for treatment of malignant pleural effusions. From May 1993 to May 1995, 21 patients with non-small cell lung cancer (NSCLC) and cytologically documented malignant pleural effusion entered the study. After complete needle drainage of the effusion, a dose of 9 x 10(6) international units (IU) rhIL-2 was injected intracavitarily. The drug was injected on the first and second day each week for 3 weeks, in relation to the presence of effusion. Complete response (according to the criteria reported by Paladine st al.) was achieved in 7 of the 21 patients (33%), and partial response in 6 of the 21 patients (29%), with a median duration of 8 months (range 4-10 months). The treatment was well tolerated by all patients. Intracavitary administration of low-dose recombinant human interleukin-2 in malignant pleural effusion due to non-small cell lung cancer is an effective and well tolerated therapeutic strategy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1122-0643
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
225-8
pubmed:dateRevised
2008-6-2
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion.
pubmed:affiliation
Division of Pneumology, Azienda Ospedaliera di Verona, Italy.
pubmed:publicationType
Journal Article